Madrigal Pharmaceuticals (MDGL) Net Cash Flow Growth (3y) (2013 - 2026)
Madrigal Pharmaceuticals (MDGL) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 15.54 Bn | - | 28.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.55% |
| Dec 31, 2025 | -33.06% |
| Sep 30, 2025 | 162.30% |
| Jun 30, 2025 | -38.58% |
| Mar 31, 2025 | 140.48% |
| Dec 31, 2024 | -117.44% |
| Sep 30, 2024 | -165.68% |
| Jun 30, 2024 | -125.88% |
| Mar 31, 2024 | 281.06% |
| Dec 31, 2023 | 39.02% |
| Sep 30, 2023 | -32.39% |
| Jun 30, 2023 | -96.16% |
| Mar 31, 2023 | -134.75% |
| Dec 31, 2022 | 102.97% |
| Sep 30, 2022 | -29.03% |
| Jun 30, 2022 | -23.98% |
| Mar 31, 2022 | 37.65% |
| Dec 31, 2021 | -38.69% |
| Sep 30, 2021 | 27.42% |
| Jun 30, 2021 | -26.97% |